Renalytix Valuation
Is RNLX.Y undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RNLX.Y when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate RNLX.Y's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate RNLX.Y's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RNLX.Y?
Key metric: As RNLX.Y is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is RNLX.Y's PS Ratio? | |
|---|---|
| PS Ratio | 13.7x |
| Sales | US$2.35m |
| Market Cap | US$32.16m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 16.6x |
| Enterprise Value/EBITDA | -1.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does RNLX.Y's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.3x | ||
DRIO DarioHealth | 1.2x | 28.1% | US$28.8m |
ONMD OneMedNet | 28.9x | n/a | US$29.5m |
VSEE VSee Health | 2.9x | n/a | US$23.2m |
CCLD CareCloud | 0.4x | 1.7% | US$45.8m |
RNLX.Y Renalytix | 13.7x | 126.2% | US$25.7m |
Price-To-Sales vs Peers: RNLX.Y is expensive based on its Price-To-Sales Ratio (13.7x) compared to the peer average (8.3x).
Price to Sales Ratio vs Industry
How does RNLX.Y's PS Ratio compare vs other companies in the US Healthcare Services Industry?
Price-To-Sales vs Industry: RNLX.Y is expensive based on its Price-To-Sales Ratio (13.7x) compared to the US Healthcare Services industry average (2.1x).
Price to Sales Ratio vs Fair Ratio
What is RNLX.Y's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 13.7x |
| Fair PS Ratio | 29x |
Price-To-Sales vs Fair Ratio: RNLX.Y is good value based on its Price-To-Sales Ratio (13.7x) compared to the estimated Fair Price-To-Sales Ratio (29x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Lantheus Holdings
US$6.3b
Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
LNTH
US$90.52
7D
18.8%
1Y
27.5%
Elevance Health
US$93.4b
Operates as a health benefits company in the United States.
ELV
US$402.55
7D
0.5%
1Y
-15.7%
electroCore
US$72.3m
A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.
ECOR
US$11.21
7D
16.2%
1Y
99.5%